Is NAP an additional neuroprotector in Alzheimer's disease?

Alzheimer's disease (AD) is the most common cause of dementia in late life. The objective of utilizing proteomic techniques in this study was to identify protein biomarkers associated with NAP (NAPVSIPQ, amino acid sequence from 354 to 361) treated with human neuroblastoma cells SH-SY5Y. Experimental results suggested that stathmin was a protein marker for NAP-induced neuroprotective activity in neuroblastoma cells. Thus, the use of NAP is suggested as a treatment to provide additional protection in patients with AD.